Ginkgo Bioworks Reports $50 Million in Q2 Revenue, Focuses on Biosecurity and Automation Growth

In the second quarter of 2025, Ginkgo Bioworks reported $50 million in revenue, a decrease from the same period last year. The decline was driven by lower biosecurity-related revenue, but the company's Cell Engineering segment saw an 8% increase in revenue, primarily due to stronger relationships with biopharma and government clients. Despite the decrease in revenue, Ginkgo reported a significant improvement in net loss and adjusted EBITDA compared to the previous year, with cash, cash equivalents, and marketable securities totaling $474 million as of June 30, 2025.

CEO Jason Kelly highlighted the growing demand for Ginkgo's automation and data generation capabilities, particularly in AI-powered biology. The company achieved its target of $250 million in annualized cost reductions ahead of schedule, and made progress in its automation and data generation services. Looking ahead, Ginkgo reaffirmed its full-year revenue guidance, expecting total revenue for 2025 to be in the range of $167 million to $187 million.